At 12 months, the estimated prices of progression-free survival were very similar for patients who have been receiving dasatinib and those who were getting imatinib . None of the sufferers in whom a major molecular response was accomplished have had progression to the accelerated or blastic phase through the current follow-up. At 12 months, the estimated prices of overall survival had been 97 percent among individuals receiving dasatinib and 99 percent among those receiving imatinib. Safety Drug-related adverse events associated with both treatments were primarily grade 1 or grade 2 events .The info analyses were performed with the use of SAS software, version 9.1 . All reported P values are two-sided, and values of less than 0.05 were thought to indicate statistical significance. To maintain the study blinding, an independent external statistician performed the efficacy analysis.2 months . A total of 60 cases of hepatitis E were confirmed, including 23 in the original study23 and 37 in the extended study. The cumulative incidence of hepatitis E was significantly reduced the vaccine group than in the control group ; 53 of the full cases were detected in the control group, and 7 had been detected in the vaccine group . Of the 7 individuals in the vaccine group who acquired hepatitis E, 3 acquired received all three dosages of the vaccine, 1 had received two doses, and 3 had received one dose.